IDEAYA Biosciences Q3 2024 Update

TL;DR

IDEAYA's Q3 2024 10-Q shows progress on Werner Helicase and recent stock offerings.

AI Summary

IDEAYA Biosciences, Inc. filed its 10-Q for the period ending September 30, 2024. The company reported on its Werner Helicase Program and its San Diego, California lease agreements. Key financial events include a Follow-On Public Offering on July 11, 2024, and an At-The-Market Offering during the first nine months of 2024.

Why It Matters

This filing provides insight into IDEAYA's ongoing clinical programs and financial activities, crucial for investors tracking its progress in drug development.

Risk Assessment

Risk Level: medium — Biotech companies like IDEAYA face inherent risks due to the long and uncertain drug development process.

Key Numbers

• 2024-09-30 — Reporting Period End (Covers the third quarter of 2024)
• 2024-07-11 — Follow-On Public Offering (Significant financing event)

Key Players & Entities

• IDEAYA Biosciences, Inc. (company) — Filer
• 2024-09-30 (date) — Reporting Period End Date
• Werner Helicase Program (program) — Key Program Mentioned
• San Diego, California (location) — Lease Agreement Location
• 2024-07-11 (date) — Follow-On Public Offering Date
• Andres Ruiz Briseno (person) — Mentioned Individual

FAQ

Key Financial Figures

• $0.0001 — nge on which registered Common Stock, $0.0001 par value per share IDYA Nasdaq Glo

Filing Documents

• idya-20240930.htm (10-Q) — 1746KB
• idya-ex10_1.htm (EX-10.1) — 557KB
• idya-ex10_2.htm (EX-10.2) — 182KB
• idya-ex31_1.htm (EX-31.1) — 15KB
• idya-ex31_2.htm (EX-31.2) — 15KB
• idya-ex32_1.htm (EX-32.1) — 12KB
• img189414369_0.jpg (GRAPHIC) — 3KB
• 0000950170-24-120675.txt ( ) — 8175KB
• idya-20240930.xsd (EX-101.SCH) — 1159KB
• idya-20240930_htm.xml (XML) — 1120KB

—FINANCIAL INFORMATION

PART I—FINANCIAL INFORMATION 4

Financial Statements (Unaudited)

Item 1. Financial Statements (Unaudited) 4 Condensed Balance Sheets 4 Condensed Statements of Operations and Comprehensive Loss 5 Condensed Statements of Stockholders' Equity 6 Condensed Statements of Cash Flows 8 Notes to Condensed Financial Statements (Unaudited) 9

Management's Discussion and Analysis of Financial Condition and Results of Operations

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations 28

Quantitative and Qualitative Disclosures About Market Risk

Item 3. Quantitative and Qualitative Disclosures About Market Risk 48

Controls and Procedures

Item 4. Controls and Procedures 48

—OTHER INFORMATION

PART II—OTHER INFORMATION 49

Legal Proceedings

Item 1. Legal Proceedings 49

Risk Factors

Item 1A. Risk Factors 49

Unregistered Sales of Equity Securities and Use of Proceeds

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 50

Defaults Upon Senior Securities

Item 3. Defaults Upon Senior Securities 50

Mine Safety Disclosures

Item 4. Mine Safety Disclosures 50

Other information

Item 5. Other information 50

Exhibits

Item 6. Exhibits 51

—FINANCIA L INFORMATION

PART I—FINANCIA L INFORMATION

Financi al Statements (UNAUDITED)

Item 1. Financi al Statements (UNAUDITED). IDEAYA Biosciences, Inc. Condensed Bal ance Sheets ( in thousands, except share and per share amounts ) ( Unaudited ) September 30, December 31, 2024 2023 Assets Current assets Cash and cash equivalents $ 400,283 $ 157,018 Short-term marketable securities 519,746 368,096 Accounts receivable 20 18 Prepaid expenses and other current assets 12,165 7,500 Total current assets 932,214 532,632 Restricted cash 911 757 Long-term marketable securities 280,128 107,492 Property and equipment, net 8,235 6,164 Right-of-use assets 18,385 2,246 Other non-current assets — 25 Total assets $ 1,239,873 $ 649,316 Liabilities and Stockholders' Equity Current liabilities Accounts payable $ 12,567 $ 6,598 Accrued liabilities 28,092 18,756 Operating lease liabilities, current — 1,747 Total current liabilities 40,659 27,101 Long-term operating lease liabilities 18,796 1,125 Total liabilities 59,455 28,226 Commitments and contingencies (Note 6) Stockholders' equity Preferred stock, $ 0.0001 par value, 10,000,000 shares authorized as of September 30, 2024 and December 31, 2023; no shares issued and outstanding as of September 30, 2024 and December 31, 2023 — — Common stock, $ 0.0001 par value, 300,000,000 shares authorized as of September 30, 2024 and December 31, 2023; 86,357,856 and 65,039,369 shares issued and outstanding as of September 30, 2024 and December 31, 2023 9 7 Additional paid-in capital 1,669,102 968,885 Accumulated other comprehensive income 3,836 562 Accumulated deficit ( 492,529 ) ( 348,364 ) Total stockholders' equity 1,180,418 621,090 Total liabilities and stockholders' equity $ 1,239,873 $ 649,316 The accompanying notes are an integral part of these condensed financial statements. 4 IDEAYA Biosciences, Inc. Condensed Statements of

View Full Filing

View this 10-Q filing on SEC EDGAR